CRBPCorbus Pharmaceuticals Inc.Signing up patients
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Solid Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 156 (planned)
- Started
- Dec 4, 2024
- Main results expected
- Nov 1, 2026
- Fully finished
- Dec 1, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurance of Dose-limiting toxicities
Measured over: 28 days
Characterize the safety of CRB-601 in combination anti-PD(L)1 therapy
Measured over: 6 months
To evaluate the efficacy of CRB-601 in terms of DCR when administered in combination with anti-PD(L)-1
Measured over: 6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06603844 · record last updated 2025-06-03 · checked 2026-11-09 15:47 UTC